Argenx stock gains backing as Barclays lifts target after strong VYVGART growth

Published on 09/08/2026 at 17:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock is drawing renewed analyst support as Barclays raises its price target alongside robust second-quarter revenue growth driven by VYVGART. Investors are watching how the immunology specialist turns its flagship drug into a broader portfolio.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) is trading with fresh analyst support after a target hike from Barclays, while the company highlights strong second-quarter revenue momentum driven by its autoimmune drug VYVGART as of September 8, 2026.Zonebourse

Barclays raises its view on Argenx

According to Zonebourse, Barclays reaffirmed its positive stance on Argenx on September 8, 2026, maintaining a buy rating on the stock and lifting its euro-denominated price target from EUR 1,000 to EUR 1,100. This implies about 10 percent upside from the latest Euronext Brussels real-time quote around EUR 868.40 as of September 8, 2026, and roughly 21.12 percent year-to-date performance despite a mild 2.03 percent decline since the start of the year.

The same data snapshot shows Argenx shares marginally lower by 0.12 percent in real-time trading on Euronext Brussels around EUR 868.40 on September 8, 2026, underlining that the target increase is based more on fundamentals and medium-term growth expectations than on an immediate price spike.Zonebourse

Second-quarter revenue highlights and growth drivers

At the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, Argenx management pointed to a second-quarter revenue figure of USD 1.5 billion, underscoring the continuation of a strong growth trajectory for VYVGART, also known as efgartigimod.Investing.com The company explained that this quarterly revenue was supported by sales in myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and seronegative MG, reflecting broader uptake across neuromuscular indications.

Compared with earlier estimates for the MG opportunity, Argenx now sees a materially larger market. Management indicated that the addressable MG patient pool has expanded from an initial 17,000 patients to about 60,000 patients, including approximately 25,000 in earlier therapy lines, 7,000 with ocular MG, 11,000 with seronegative MG and 17,000 with refractory MG.Investing.com For investors, this quantified expansion of the target population is an important backdrop for the USD 1.5 billion second-quarter revenue figure, as it suggests that VYVGART’s growth runway is far from exhausted.

Argenx also told conference participants that the launch of VYVGART in seronegative MG has started “very successfully”, with strong uptake among patients and payers, and that four out of five neurologists now report choosing VYVGART as their first-line biologic when initiating such therapy.Investing.com This physician preference, combined with the broadened MG and CIDP reach, helps explain how the company achieved the USD 1.5 billion revenue mark in the second quarter and why Barclays and other analysts are comfortable projecting further growth.

Risk factors: competition, regulation and portfolio dependence

Despite the impressive top-line growth, Argenx management acknowledged at the same Wells Fargo event that the company faces several tangible risks as it moves beyond neuromuscular diseases. These include ongoing regulatory processes with agencies such as the United States Food and Drug Administration, competitive pressure in larger autoimmune indications and the operational challenge of expanding into broader, more crowded disease areas.Investing.com The company’s mission is to evolve from being perceived mainly as a “VYVGART company” to a diversified immunology innovator, but that transformation requires successful execution of multiple clinical and commercial programs.

Competition is one of the key counter-factors investors monitor. In myositis, Argenx expects room for more than one therapy, but management noted that a rival candidate such as Brepocitinib from Roivant could reach the market first.Investing.com Argenx argues that its own Phase III data and safety profile for VYVGART are competitive, yet the timing and outcome of regulatory decisions could influence how quickly the franchise can expand into rheumatology and other indications.

Pipeline expansion beyond VYVGART

To reduce concentration risk on a single molecule, Argenx is building out a broader immunology pipeline. At the Wells Fargo conference the company outlined “Vision 2030”, a long-term plan to treat about 50,000 patients across 10 disease areas by the end of the decade and to bring five new molecules into late-stage development.Investing.com This strategy hinges on identifying “white space” indications – conditions that are underdiagnosed, under-treated and often overlooked by larger pharmaceutical companies – such as immuno-mediated necrotizing myopathy, ocular MG and seronegative MG.

One notable addition to the portfolio is FB102, obtained through the recently finalized acquisition of Forte Biosciences. FB102 is a CD122 inhibitor targeting IL-15 and IL-2 signaling pathways, and Argenx is investigating it in indications such as vitiligo, alopecia areata and celiac disease.Investing.com The company described Phase II data in vitiligo as the key de-risking element behind the acquisition and is currently running an exploratory Phase II “learning study” in celiac disease, including an eight-week gluten challenge to inform future trial design.

Alongside FB102, Argenx is advancing empasiprubart, its second FcRn inhibitor, in Phase III trials for motor neuron disease and exploring its potential in CIDP and graft-versus-host disease.Investing.com The primary endpoint in the motor neuron study is non-inferiority versus intravenous immunoglobulin (IVIG), with superiority assessed as a secondary outcome. Management has argued that demonstrating non-inferiority alone would already represent a compelling package for market introduction, which could complement VYVGART and support the Vision 2030 patient and molecule targets.

Representative product: VYVGART at the center of Argenx’s growth

VYVGART, Argenx’s flagship FcRn inhibitor, remains at the heart of the company’s current revenue and growth profile. In the second quarter of 2026, VYVGART-driven sales across MG, CIDP and seronegative MG indications contributed significantly to the USD 1.5 billion revenue figure, illustrating how one product can support a multi-indication franchise when backed by strong clinical data and physician adoption.Investing.com

Stock level and market context

Based on the real-time Euronext Brussels data snapshot cited by Zonebourse, Argenx stock was quoted around EUR 868.40 on Euronext Brussels as of September 8, 2026, down 0.12 percent on the day and about 2.03 percent lower since the start of the year, while still up roughly 21.12 percent year-to-date. With Barclays’ raised target now at EUR 1,100, the shares trade below both that target and the recent closing reference around USD 1,010.93 used in a consensus overview, leaving room for potential alignment if VYVGART and pipeline execution continue to deliver on the second-quarter revenue momentum.Zonebourse